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Circulating Extracellular Vesicles in Stroke
Patients Treated With Mesenchymal Stem Cells:
A Biomarker Analysis of a Randomized Trial
Oh Young Bang , MD, PhD; Eun Hee Kim, PhD; Yeon Hee Cho , MS; Mi Jeong Oh, MS; Jong-Won Chung , MD, PhD;
Won Hyuk Chang , MD, PhD; Yun-Hee Kim , MD, PhD; Seong Wook Yang , PhD; Michael Chopp , PhD
BACKGROUND: Mesenchymal stem cells (MSCs) secrete trophic factors and extracellular vesicles (EVs). However, the level
and role of EVs after MSC therapy in patients with stroke are unknown. We investigated whether circulating EVs and trophic
factors are increased after MSCs and are related to the therapeutic benefits in the STARTING-2 trial (Stem Cell Application
Researches and Trials in Neurology-2) participants.
METHODS: In this prospective randomized controlled trial, patients with chronic major stroke were assigned, in a 2:1 ratio, to receive
autologous MSC intravenous injection (MSC group, n=39) or standard treatment (control group, n=15) and followed for 3 months.
Detailed clinical assessment and neuroplasticity on diffusion tensor image and resting-state functional magnetic resonance imaging
were evaluated. Serial samples were collected, before/after MSCs therapy. The primary outcome measure was circulating factors
that are associated with the clinical improvement in the Fugl-Meyer Assessment (secondary end point of the trial) and neuroplasticity
on diffusion tensor image and resting-state functional magnetic resonance imaging. Additional outcome measures were microRNAs
and trophic factors enriched in the plasma EVs, obtained using quantitative polymerase chain reaction and ELISA, respectively.
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RESULTS: Circulating EV levels were increased ≈5-fold (mean±SD, from 2.7×109±2.2×109 to 1.3×1010±1.7×1010 EVs/
mL) within 24 hours after injection of MSCs (P=0.001). After adjustment of age, sex, baseline stroke severity, and the
time interval from stroke onset to treatment, only the EV number was independently associated with improvement in motor
function (odds ratio, 5.718 for EV numberLog [95% CI, 1.144–28.589]; P=0.034). Diffusion tensor image and resting-state
functional magnetic resonance imaging showed that integrity of the ipsilesional corticospinal tract and intrahemispheric motor
network were significantly correlated with circulating EV levels, respectively (P<0.05). MicroRNAs related to neurogenesis/
neuroplasticity (eg, microRNA-18a-5p) were significantly increased in circulating EVs after MSC therapy (P=0.0479). In
contrast, trophic factor levels were not changed after MSC therapy.
CONCLUSIONS: This trial is the first to show that treatment of ischemic stroke patients with MSCs significantly increases
circulating EVs, which were significantly correlated with improvement in motor function and magnetic resonance imaging
indices of plasticity.
REGISTRATION: URL: https://wwww.clinical trials.gov; Unique identifier: NCT01716481.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
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S

troke is the leading cause of physical disability among adults. Stem cell therapy is a potential
regenerative strategy for patients with neurological

deficits. Several clinical trials of mesenchymal stem cell
(MSC) therapy have been conducted in patients with
stroke.1–7 Although most MSC therapies appeared to be
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Nonstandard Abbreviations and Acronyms
Ang-1
angiotensin 1
BDNF
brain-derived neurotrophic factor
CST
corticospinal tract
DTI
diffusion tensor image
EV
extracellular vesicle
FMA
Fugl-Meyer Assessment
GO
gene ontology
HRP
horseradish peroxidase
KEGG	Kyoto Encyclopedia of Genes and
Genomes
L1CAM
L1 cell adhesion molecule
miRNA
microRNA
MRI
magnetic resonance imaging
MSC
mesenchymal stem cell
NSE
neuron-specific enolase
rs-fMRI	resting state functional magnetic
resonance imaging
SDF-1
stromal cell-derived factor-1
STARTING-2	Stem Cell Application Researches
and Trials in Neurology-2
VEGF
vascular endothelial growth factor
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of some benefit, their effects were modest and heterogeneous among patients.
We have recently reported the results of the STARTING-2 trial (Stem Cell Application Researches and Trials
in Neurology-2), a randomized controlled trial of intravenous application of autologous MSCs, expanded with
autologous serum.7 In this trial, changes in detailed motor
function and functional outcome were measured over 90
days after randomization to either the MSC group or the
standard care group. Multimodal brain magnetic resonance imaging (MRI), including resting-state functional
MRI (rs-fMRI) and diffusion tensor imaging (DTI), was
performed. The secondary analyses showed significant
improvements in detailed motor function in the MSC
group compared with the control group, but there was a
relatively large variation in the changes of motor function
among patients of the MSC therapy. In this trial, a prespecified biomarker study was performed to investigate
possible mechanisms of action of MSCs.
MSCs secrete a variety of bioactive substances,
including trophic factors and extracellular vesicles (EVs),
into the injured brain, which may be associated with
enhanced neurogenesis, angiogenesis, neurite outgrowth and remodeling, and neuroprotection. However,
the level and role of EVs after MSC therapy in patients
with stroke are unknown. We hypothesized that the
effects of MSC therapy are mediated via EVs. Thus, we
serially measured the circulating trophic factors and EVs,
before and after intravenous application of MSCs. We
2   June 2022
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investigated whether these circulating factors are independently associated with clinical improvement in the
Fugl-Meyer Assessment (FMA; the secondary end point
of the trial) and neuroplasticity measured using DTI and
rs-fMRI. In addition, we investigated the EV cargo, that is,
microRNAs (miRNAs) and proteins, to identify the possible mechanisms of action of MSC therapy. This was a
preplanned secondary analysis.

METHODS
The data that support the findings of this study are available
from the corresponding author upon reasonable request.

Trial Design
The STARTING-2 trial (NCT01716481) was an investigatorinitiated, prospective, randomized, open-label, controlled trial
with blinded outcome evaluation (PROBE design [prospective, randomized, open-label, controlled trial with blinded outcome evaluation]). The details of trial protocol, bone marrow
aspiration, MSC isolation, cell preparation, and intravenous
infusion are described elsewhere.7,8 Chronic cases of stroke
with fixed neurological deficits were included and followed
for 3 months. Eligible participants were adult, aged 30 to 75
years, who had moderate-to-severe persistent neurological
deficits (National Institutes of Health Stroke Scale score of
6–21 points), stroke observed within 90 days of the onset of
symptoms, and nonlacunar infarcts within the middle cerebral artery territory, but sparing more than a half of ipsilateral
subventricular zone. We excluded patients who had a significant disability before the current stroke, whom we defined
as those having a prestroke modified Rankin Scale score of
≥2. We also excluded patients with lacunar stroke, hemorrhagic stroke, and recurrent stroke within 7 days of screening. Detailed information on inclusion and exclusion criteria
is reported elsewhere.7,8 Participants were enrolled from 4
University Medical Centers and transferred to the Samsung
Medical Center to receive comprehensive rehabilitation and
undergo serial dedicated MRI and biomarker study.
Participants were assigned, in a 2:1 ratio, to receive intravenous MSC injection (MSC group) or standard care alone (control group), using computer-generated random permuted blocks
with blocks of 6 subjects. After randomization, all participants
received conventional rehabilitation therapy (physical, occupational, speech/language, or cognitive rehabilitation therapy as
needed) during the inpatient rehabilitation period. Participants
in the MSC group underwent MSC treatment. Expanded autologous MSCs at 1×106 cells/kg (maximum, 1.2×108) were
infused via the antecubital vein with 5×106 cells/mL of normal saline over 10 minutes at 55.9±19.1 days after the onset
of stroke. Comprehensive and objective measurements using
multimodal MRI and detailed functional assessments were
performed. The clinical trial protocol and consent form were
approved by the Korean Food and Drug Administration (No.
12218) and the Institutional Review Board of the Samsung
Medical Center (IRB-2011-10-047). The trial was registered and reported according to the Consolidated Standards
of Reporting Trials statement. Written informed consent was
obtained from all patients or their first-degree relatives.
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.121.036545
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Changes in detailed motor function and the functional outcome
were evaluated by the modified Rankin Scale score and FMA.
Changes of each score were serially measured over a period of
90 days after randomization. We designated each stroke patient
as either a good or poor responder according to the minimal
clinically important difference in the FMA.9,10 Good responders
for motor recovery were defined as those having a total score
of >15 (FMA-T), an upper limb score of >9 (FMA-UL), and a
lower limb score of >6 (FMA-LL) from baseline to 90 days.
Multimodal brain MRI, including rs-fMRI and DTI, was performed as described elsewhere.11 In brief, to measure tractwise DTI-derived parameters, a template corticospinal tract
(CST) generated from the healthy controls was used instead
of tracking the CST in every patient. The use of a template
CST has been suggested as a standardized approach to measure the integrity of the CST in patients with stroke using DTI
data.12 In every patient, DTI-derived parameters in the native
space were transformed to the same standard space on
which the template CST was placed. The tract-wise fractional
anisotropy value was calculated as the average of the parameters read over the extent of the template CST on the ipsilesional side. To extract FA values of the CST, individual DTI
data were preprocessed using the FMRIB Diffusion Toolbox
implemented in the FSL software package 5.0.9 (FMRIB
Software Library, FMRIB, Oxford, United Kingdom; http://
www.fmrib.ox.ac.uk/fsl). The DTIfit algorithm was used to fit
a tensor model and reconstruct FA maps. The FA maps were
registered to the MNI standard space (FMRIB58_FA standard-space image) using the nonlinear registration algorithms
of the tract-based spatial statistics technique. Lesioned voxels
were masked out, and stroke lesion was not considered during the spatial registration. The spatially normalized FA maps
were visually checked. To obtain the FA value of the CST, the
CST template descending from the primary motor cortex (M1)
obtained from probabilistic tractography in the 9 healthy DTI
data was used.2 The CST was binarized and masked on the
spatially normalized FA maps. The FA values of the CST were
obtained by averaging the FA values within each region. The
proportional FA values (affected/unaffected hemisphere)
were used as the integrity measure for each region. Because
we included MCA infarction patients with moderate-to-severe
motor involvement, all participants had infarct involvement
of the CST. The preprocessing of the rs-fMRI data included
slice timing correction, spatial realignment, lesion-masked
spatial normalization, and spatial smoothing with a 6-mm
full-width half-maximum gaussian Kernel. All processes
were performed with the SPM12 package (Welcome Trust
Centre for Neuroimaging, University College London, London,
United Kingdom; http://www.fil.ion.ucl.ac.uk/spm). Nuisance
signals were removed with a linear regression of 9 parameters, including 6 head motion parameters and 3 temporal
parameters for each of the white matter, ventricle, and global
signals. Band-pass filtering between 0.009 and 0.08 Hz and
linear detrending were performed to remove constant offsets and linear trends. These processes were performed with
MATLAB R2014b (Mathworks, Natick, MA). The functional
network was constructed with 24 predefined (motor related)
regions obtained from a previous meta-analysis13 from 36
neuroimaging studies for upper extremities of patients with
stroke. Lesioned voxels were masked out. The network was
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.121.036545

constructed by calculating the Pearson correlation for the
mean time course of each region defined as the 10-mmdiameter sphere around the predefined MNI coordinates.

Measurement of Circulating EVs and Trophic
Factors
We serially measured the circulating EVs and trophic factors,
before and after intravenous application of MSCs. Sampling
was performed before MSC treatment (the day before and
immediately before MSC injection) and after treatment (within
24 hours of treatment [postTxD0], posttreatment day 3 [postTxD3], day 7 [postTxD7], day 14 [postTxD14], and day 90 [postTxD90]) for the MSC group and for the control group at 30
days (preTx), 44 days (postTx14), and 120 days (postTx90)
of enrollment. Plasma samples were prepared from citrated
whole blood following immediate centrifugation for 15 minutes
at 2000g and stored at –80 °C until further analyses. To isolate and measure EVs, citrate plasma was diluted 1:1 in 0.22
µm filtered PBS and centrifuged at 10 000g for 15 minutes at
4 °C. EVs from the precleared supernatant were then pelleted
at 100 000g for 1 hour. Centrifugation steps were performed
at 4 °C using an Optima TLX ultracentrifuge (Beckman Coulter,
Brea, CA) and a TLA120.2 rotor. Pellets were resuspended in
filtered PBS and centrifuged again at 100 000g for 60 minutes
at 4 °C using the same tubes. The final pellet containing EVs
was resuspended in 100 µL PBS.
For optimal analysis, EVs were prediluted in vesicle-free
water, and the concentration and size distribution of EVs were
characterized using a NanoSight NS300 instrument (Malvern,
Worcestershire, United Kingdom). The mean size and concentration (particles/mL) were calculated by integrating the data
from 3 individual measurements.
The direct visualization of EVs was examined by Cryotransmission electron microscopy. Carbon grids (Quantifoil,
R1.2/1.3, 200 Mesh, Electron Microscopy Solutions) were
made hydrophilic surface with glow-discharged in Pelco
EasiGlow system. An aliquot (4 μL) of samples was applied on
to the carbon side of EM grid and blotted for 1.5 s with humidity and temperature of 100% and 4 °C. Then the sample was
plunge frozen into the precooled liquid ethane with Vitrobot
Mark IV (FEI). The samples were analyzed by cryo-electron
microscope Talos L120C (FEI) at 120 kv.
Twenty micrograms of EV protein was separated by sodium
dodecyl sulphate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA).
The membrane was incubated with primary antibodies against
CD63, flotillin-1, and HSP70 ([heat shock protein 70]; 1:1000;
Cell Signaling Technology, Beverly, MA) or calnexin (1:1000;
Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4 °C and
then was incubated with HRP (horseradish peroxidase)-conjugated secondary antibodies (1:1000; anti-rabbit; Cell Signaling
Technology) for 2 hours. Proteins were detected using a chemiluminescence substrate from ThermoFisher Scientific, Inc (Waltham,
MA), and were visualized on x-ray film (Agfa, Mortsel, Belgium).
We quantified levels of trophic factors in plasma using
ELISAs. ELISAs were performed using commercial kits according to the manufacturer’s instructions. The following ELISA kits
were used: human VEGF (vascular endothelial growth factor;
R&D Systems, Minneapolis, MN), human CXCL12 (C-X-C motif
chemokine ligand 12)/SDF-1 (stromal cell-derived factor-1;
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R&D Systems), human BDNF (brain-derived neurotrophic factor; R&D Systems), and human NSE (neuron-specific enolase;
R&D Systems).

Measurement of miRNAs and Proteins Within
Circulating EVs

Downloaded from http://ahajournals.org by on May 2, 2022

We measured the levels of miRNA within EVs sequentially
(before treatment, on the day of treatment, 14 days of treatment,
and 90 days of treatment) in both control and MSC groups. The
levels of miRNAs within EVs related to therapeutic efficacy of
stem cells and potential recovery after stroke were measured in
individual patients using the quantitative polymerase chain reaction technique and analyzed by 2−ΔCt quantitative method. The
total RNA of EVs was extracted using the miRNeasy Serum/
Plasma Kit (Qiagen, Hilden, Germany) and XENOPURE miRNA
extraction Kit (Xenohelix, Incheon, Korea; CAT: 93667873-EV)
in accordance with the manufacturer’s instructions. The concentration of RNA was quantified by NanoDrop 1000 (NanoDrop,
Wilmington, DE). The primers for the miRNAs were performed
by TaqMan MicroRNA Assays (Applied Biosystems, Foster
City, CA). We selected a total of 16 miRNAs to be analyzed;
miR-17-92 (miR-17-3p, 18a-5p, miR-20a-5p, and miR-92-1)
and miR-133b, which are associated with neuronal plasticity,
neurogenesis, and oligodendrogenesis14,15; miR-126-5p, miR132-3p, miR-181b-5p, and miR-494-3p, which are involved
in angiogenesis16–19; miR-19a-3p, miR-146a-5p, miR-210-3p,
and miR-223-3p, which are related to cytoprotection/antiinflammation20–23; and miR-21-5p and miR-196a-5p, which are
involved in recovery after stroke.24,25 The absolute copy numbers
of 7 miRNAs within EVs were determined by performing the
XENO-Q miRNA detection assay (Xenohelix, Incheon, Korea;
CAT: 93661000), following the manufacturer’s instructions. This
method relies on the sequence-specific hybridization between
a fixed amount of Xeno nucleic acid–based sensors and their
target miRNAs that precisely calculates the copy number of
multiple target miRNAs. We detected the function of expressed
miRNAs in target genes using the Kyoto Encyclopedia of Genes
and Genomes (KEGG) and gene ontology (GO) pathway analysis. GO analysis and KEGG pathway enrichment analysis were
performed by the miRWalk2.0 web-based tool (http://zmf.umm.
uni-heidelberg.de/apps/zmf/mirwalk2/).
Circulating brain-derived EVs were analyzed using immune
capture for neuronal surface antigen LICAM (L1 cell adhesion
molecule; also known as CD171) to selectively isolate EVs
enriched for neuronal origin.26,27 The level of trophic factors
related to neuronal recovery in brain-derived EVs was serially
measured to evaluate the changes of these levels in the brain
after MSC treatment. We defibrinated plasma samples using
thrombin (System Biosciences, Inc, Mountainview, CA), precipitated total EVs using particle precipitation by Exoquick (System
Biosciences, Inc), and immunoprecipitated brain-derived EVs
expressing L1CAM. Proteins of L1CAM-positive brain-derived
EVs were quantified by electrochemiluminescence using
the Mesoscale Discovery platform and kits, including human
VEGF-a, BDNF, and b-NGF ([beta-nerve growth factor]; catalog
No. K151ACL-1, MESO SECTOR S 600, Gaithersburg, MD).

Statistical Analysis
Differences in discrete variables between the groups were
examined using the χ2, Fisher exact, or Mann-Whitney U test as
4   June 2022
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appropriate. Differences in continuous variables were examined
using 1-way ANOVA, Kruskal-Wallis test, or t test. In addition,
independent factors for the clinical improvement were evaluated using multivariate logistic regression. Adjustment variables
in the multivariable regression models were selected from the
literature and selected as age, sex, the National Institutes of
Health Stroke Scale at the time of MSC injection, MSC injection,
and circulating EV levels after MSC injection for the MSC group
and the level at the corresponding time in the control group.
Significance levels were set at 2-tailed P of <0.05. All statistical
analyses were performed using commercially available software
(STATA, version 13.1; Stata Corp, College Station, TX).

RESULTS
Baseline Characteristics
All the 54 patients (women, n=27; mean age, 63.4±13.9
years old; control group of 15 patients and MSC group of
39 patients) enrolled in the trial participated in this study.
Baseline characteristics are shown in Table S1. Nine of
39 patients of the MSC group and 2 of 15 patients of
the control group were classified as good responders
according to the FMA-T score after 90 days of intervention. Although good responders were numerically higher
in the MSC group than in the control group, there was no
significant difference (P>0.05).

Plasma Trophic Factor Levels Were Not
Changed After MSC Therapy
The levels of circulating cytokines, chemokines, and trophic factors were not different between the control and
MSC groups (Figure 1). In addition, there were no differences in the levels between patients who showed clinical
improvement in motor function and those who did not
(Figure S1A through S1C).

Plasma EV Levels Are Increased in Patients
With MSC Treatment and Correlated With
Improvement of Motor Function
Most EVs had a round shape with an electron dense
structure observed by Cryo-transmission electron
microscopy analysis, and their mean (SD) diameter was
156.98 (17.5) nm, respectively (Figure 2A and 2B). The
circulating EVs were positive for EV markers including
CD63, flotillin-1, and HSP70, whereas calnexin, an EVnegative marker, was not detected (Figure 2C).
Pretreatment EV levels varied among patients
(mean±SD, 4.5×109±7.9×109 EVs/mL) and were not
different between the control and MSC groups (P>0.05).
Before injection of MSCs, circulating EV levels were serially measured (n=21), which showed that the levels of
EV did not change with time (Figure S2).
The number of EVs in the blood were measured
immediately after MSC therapy. The level of EVs
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.121.036545
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Figure 1. The temporal profiles in the levels of circulating trophic factors and chemokines after mesenchymal stem cell (MSC)
therapy.
A, The temporal profiles in the levels of circulating trophic factors and chemokines on MSC group. B, The temporal profiles in the levels of
circulating trophic factors and chemokines on control group. Mean±SEM, P>0.05 in all cases. BDNF indicates brain-derived neurotrophic factor;
NSE, neuron-specific enolase; SDF-1, stromal cell-derived factor-1; and VEGF, vascular endothelial growth factor.

was significantly increased ≈5-fold (mean±SD, from
2.7×109±2.2×109 EVs/mL to 1.3×1010±1.7×1010
EVs/mL) within 24 hours after injection of MSCs
(P=0.001) The percentage increase in EV levels compared with the pretreatment levels is shown in Figure 3A
and 3B. In the MSC group, the level of circulating EVs after
MSC injection varied greatly among patients, although
the same body weight–adjusted number of MSCs were
injected. This level was marked increased in patients who
showed clinical improvement in motor function than in
those who did not show clinical improvement (EV numberLog, P=0.039 for FMA-total, P=0.023 for FMA-upper,
P=0.291 for FMA-lower; Figure 3C and 3D). Correlation
analysis showed that circulating EV numberLog after MSC
injection was significantly correlated with improvement
in motor function (r=0.444, P=0.001) but not in patients
of the control group (r=0.359, P=0.207; Figure S3). The
time interval between stroke onset and time of MSC
injection was not different between the good and poor
responders (51.0±11.7 versus 57.9±20.9 days, P>0.05).
The time interval between stroke onset to placebo injection was 53.4±11.0 days. After adjustment of age, sex,
baseline National Institutes of Health Stroke Scale, and
the time interval from stroke onset to treatment of MSCs
or placebo, only the number of circulating EVs was independently associated with clinical improvement (good
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.121.036545

responders; odds ratio, 5.718 for EV numberLog [95%
CI, 1.144–28.589]; P=0.034). In addition, the association between circulating EV levels and DTI and rs-fMRI
indices of neuroplasticity was measured on day 90 (Figure 4). Integrity of ipsilesional CST and intrahemispheric
motor network were significantly correlated with the circulating EV levels (P<0.05 in both cases), suggesting
the influence of increased EV levels on the ipsilesional
motor network, and on both anatomic and functional
recovery, in MSC-treated patients with stroke. There was
a good correlation of circulating EV numbers measured
by NanoSights with CD9 (a tetraspanines) expressing
EV levels on nano-flow cytometry and EV protein levels
measured by the microBCA method (Figure S4).

MiRNAs Related to Neurogenesis Are Increased
in Circulating EVs After MSC Therapy
In addition to the increased number of EVs, the relative
expression of miRNAs within EVs related to neuroplasticity
was increased in patients with the MSC group. Specifically,
miRNA-18a-5p was significantly increased in the MSC
group (P=0.0479; Figure 5A). The GO and KEGG analysis showed that enriched miR-18a-5p was linked to signal
pathways and biological processes related to the nervous
system development, the nerve growth factor receptor
June 2022   5
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Figure 2. Characterization of circulating extracellular vesicles (EVs).
A, EVs imaged using Cryo-transmission electron microscopy. B, Histogram representing the size distributions and concentrations of the EVs using
NanoSight. C, EV-positive markers, including CD63 (cluster of differentiation 63), flotillin-1, and HSP70 (heat shock protein 70), and EV-negative
markers, including calnexin, using Western blot (n=3).

signaling pathway, and axonal guidance (Figure 5B). The
KEGG pathways were linked to axon guidance, neurotrophin signaling, and Wnt signaling pathway. GO analysis
showed that transcription DNA dependent, nervous system development, nerve growth factor receptor signaling
pathway, and axon guidance in the biological process were
significantly associated. Other selected miRNAs measured
were not different between the groups (data not shown).

Trophic Factor Levels Are Increased in BrainDerived EVs After MSC Therapy
To evaluate the possible mechanisms of action of MSC
or MSC-derived EVs in the brain, circulating brainderived EVs were collected, and the levels of trophic
factors in these EVs were measured in all the patients
(n=15 of the control group and n=39 of the MSC
group). Compared with the pretreatment, the trophic
factor levels in the circulating brain-derived EVs were
increased at posttreatment day 3 (Figure 6). VEGF
levels were significantly increased after MSC therapy,
and the levels of BDNF and NGF (nerve growth factor) were increased but did not reach significant level,
due to the small sample size (P=0.3132 for BDNF,
P=0.0407 for VEGF, and P=0.0932 for NGF).
6   June 2022

DISCUSSION
The major finding of this study is that EV levels were
significantly increased in the blood after injection of
MSCs, especially in patients who showed improvement in motor function outcome and neuroimaging
after MSC therapy. MiRNAs related to neurogenesis
were significantly increased in circulating EVs after
MSC therapy. To the best of our knowledge, this is the
first study performed in a randomized controlled trial of
stroke, which suggests the importance of EVs in mediating the stem cell therapy.
EVs are released from various cells, including blood
cells, organs, and endothelial cells, and distribute to
organs and rapidly cleared by macrophages from blood
circulation.28 In patients with stroke, EVs in the blood can
be derived from many sources, including infarcted brain,
cerebrovasculature, platelets, and MSCs from patients’
bone marrow. However, our serial analysis of plasma EVs
showed no increase in EV levels before MSC treatment.
A pharmacokinetic analysis of mouse plasma-derived
EVs showed a balanced homeostasis by rapid secretion
and clearance of endogenous EVs.28 Moreover, patients
with chronic stroke were included in this trial precluding
the possible influence of acute stroke in EV levels.
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.121.036545
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Figure 3. The temporal profile of plasma levels of circulating extracellular vesicles (EVs) after mesenchymal stem cell
(MSC) therapy.
The level of circulating EVs was significantly increased in the MSC group (A) but not increased in the control group (B). In the MSC group, the
level of EV was significantly increased in patients who achieved a minimal clinically important difference (MCID) of the Fugl-Meyer Assessment
(FMA; C) but not in patients who achieved no MCID (D). FMA-LL indicates lower limb score of the Fugl-Meyer Assessment; FMA-T, a total score
of the Fugl-Meyer Assessment; and FMA-UL, upper limb score of Fugl-Meyer Assessment. Mean±SEM, *P=0.001, †P=0.039, ‡P=0.023.

The robust increase of plasma EV levels after systemic
administration of MSC was an unexpected and interesting finding. The number of EVs increased from 2.7×109
to 1.3×1010 EVs/mL within 24 hours after injection of
MSCs. The value appears to be larger compared with
the estimated number of EVs secreted from MSCs in the
body after MSC injection. The number of EVs increased
in the blood was calculated as ≈7×107 EVs/mL, given
that 1×106 cells/kg were injected, one MSC secreted
≈5×103 EVs in our ex vivo experiment, and blood volume
is 70 to 80 mL/kg. However, it should be noted that the
secretion rate of EVs from MSCs in the blood is much
higher than that of cell cultured EVs.28 In addition, MSCs
release EVs in response to the ischemic brain microenvironment.29 We have previously shown that treatment of
bone marrow MSCs with ischemic brain extract increased
the number of EVs released from MSCs, >100-fold.29 Further studies on the biodistribution of EVs after systemic
administration of MSCs are needed. A biodistribution
study of EVs revealed the rapid disappearance of EVs in
the blood with a very short half-life after a single intravenous injected labeled Evs,28 while an MSC biodistribution
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.121.036545

study in patients with liver cirrhosis showed that labeled
MSCs were accumulated in the organs up to day 10 after
systemic administration.30
Stem cell therapies exert their actions through paracrine
secretion effects of stem cells, such as trophic factors,
cytokines, chemokines, and EVs. MSC-derived EVs act as
key messengers between MSCs and injured cells, which is
one of the major paracrine actions of MSCs.31–33 However,
it is unknown whether EVs are indeed formed by systemically administered MSCs. Our present results show that EV
levels increased in patients after injection of MSCs. Importantly, the levels of EVs differed among patients although
the same dose-adjusted numbers of MSCs were administered in the MSC group. Furthermore, the number of EVs
was the only independent factor for the favorable clinical
and imaging outcomes. Such interindividual variation in EV
levels may, in part, explain the heterogeneity of the effects
of MSCs among patients in clinical trials of stem cells for
stroke. Our present results of a significant correlation of
anatomic and functional improvement in motor function
with numbers of plasma EVs are consistent with previous preclinical studies that showed that MSC-derived EVs
June 2022   7
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Figure 4. The association between circulating extracellular vesicle (EV) levels within 24 h after mesenchymal stem cell (MSC)
therapy and diffusion tensor imaging and resting-state functional magnetic resonance imaging indices of neuroplasticity
measured on day 90 (n=54 including both control and MSC groups).
Integrity of ipsilesional corticospinal tract (CST; A) and intrahemispheric motor network (B) was significantly correlated with the circulating EV
levels. P<0.05 in all cases except contralesional CST. FA indicates fractional anisotropy; M1, primary motor cortex; PMd, dorsal premotor area;
PMv, ventral premotor area; and SMA, supplementary motor area.

promote neural plasticity in animal models of stroke.34,35
Recently, Barzegar et al36 showed that the protective
effects of MSCs in a stroke mouse model were decreased
by blocking the formation/release of EVs from MSCs. It
is possible that trophic factors that modify the cerebral
microenvironment contribute to the efficacy of cell therapy.
A recent multicenter study of patients with nonlacunar
stroke within 24 hours from symptom onset showed that
high serum levels of VEGF, Ang-1 (angiotensin 1), G-CSF
(granulocyte colony stimulating factor), and SDF-1α at day
7 and 3 months after ischemic stroke are associated with
good functional outcome and smaller residual lesion at 1
year of follow-up.37 Therefore, we serially measured the
levels of growth factors and SDF-1α after MSC therapy.
The present study showed that levels of trophic factors and
chemokines were not changed and apparently were not
related to clinical outcome after MSC therapy. However,
we only measured a selected number of these factors, and
further studies are needed to preclude the possibility of a
contribution of other factors.
In this study, we analyzed the EV-miRNA profile and
brain-derived EV-trophic factor levels to investigate the
8   June 2022

possible mechanisms of action of MSC therapy. Biomarker
studies in clinical trials of stem cell therapy may provide
insights of action mechanisms of stem cells in patients
with stroke. In a secondary analysis of the Exenatide-PD
randomized clinical trial, the investigators measured the
levels and target pathways of circulating EVs after treatment of patients with Parkinson disease with exenatide
(a glucagon-like peptide 1 agonist).27 Our results showed
that circulating EVs contained miRNA-18a-5p, one of
miRNA-17-92 cluster, which significantly increased after
MSC therapy, and that the enriched miR-18a-5p was
linked to signal pathways and biological processes related
to neuroplasticity. Our GO and KEGG analyses are in line
with previous studies that showed bone marrow MSCderived EVs enriched with the miRNA-17-92 cluster
mediate the proliferation/survival of neuronal progenitor
cells and neuroplasticity after stroke.14,38,39 Further studies are needed to confirm our results because other individual components of the miR-17-92 cluster did not show
a similar change. However, our quantitative analysis of the
absolute copy numbers of individual miRNA-17-92 cluster using the XENO-Q miRNA detection assay showed
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.121.036545
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Figure 5. Relative expression of microRNAs related to neuroplasticity in the control and mesenchymal stem cell (MSC) group.
A, Significantly increased miRNA-18a-5p expression in the circulating extracellular vesicles (EVs) of the MSC group (P=0.0479). B, Gene
ontology (GO) of biological processes (BP) and (C) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways are presented using only the
10 most relevant terms on target genes of miR-18a-5p enriched in the EVs.

the most tested miRNA levels were numerically increased
in almost 2-fold after treatment of MSC therapy (Table
S2; Figure S5). In addition, there were similarities in the
miRNA profile between conditioned media EVs obtained
during ex vivo cultivation and plasma EVs obtained within
24 hours after injection of MSCs, suggesting that the
administered EVs have a direct impact on the plasma EVs

(Figure S6). Moreover, trophic factors related to neuronal
recovery after stroke were increased in the plasma brainderived EVs, suggesting that MSCs or MSC-EVs exert
their action via the regulation of trophic factor levels within
the recipient brain cells.
This study had some limitations. This is a preliminary
study, limited in patient populations investigated and

Figure 6. Trophic factors enriched in the brain-derived L1CAM-positive extracellular vesicles were increased after 3 d of
mesenchymal stem cell (MSC) therapy.
BDNF indicates brain-derived neurotrophic factor; con., concentration; NGF, nerve growth factor; and VEGF, vascular endothelial growth factor.
Mean±SEM, *P=0.0407.
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.121.036545
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molecular markers measured. In this study, owing to the
experimental nature of the treatment, a relatively small
number of patients were included, and only selected
miRNAs were tested because of the limitation in the
amount of plasma of trial participants. In addition, this
study included only patients with MCA infarction patients,
so limiting generalizability to most stroke patients. Second, multiple correlation analyses were performed in
this study based on the limited data set, the possibility
of type II error cannot be excluded. Characteristics of
patients, including age, stroke severity, and comorbidity,
may impact on the results of this study, but the findings
of robust increase in EVs after MSC treatment and their
correlation with recovery warrants further studies. Third,
beside MSCs, the source of EVs could be blood, endothelium, and other tissues. Further studies are needed
evaluating the pharmacokinetics and biodistribution
of MSC-derived EVs using various tagging strategies.
Fourth, the change in the clinical outcomes would be
influenced based on when the cells were injected after
stroke. Our substudy of responder analysis showed that
time from stroke onset to MSC therapy was related to
the patients’ response to MSC therapy.40 However, in the
present study, the number of circulating EV levels was
independently associated with clinical improvement after
adjustment of the time of MSC injection after stroke.
Fifth, plasma EV levels were measured at 24 h posttreatment in the MSC group, but EV levels were not measured at a comparable time point in the control group
after stroke. The EV levels could be influenced by acute
stroke or other factors unrelated to MSCs. However, in
our opinion, it is unlikely that plasma EV levels change
with time in patients with chronic ischemic stroke (Figure
S2). Lastly, the methods for quantifying EVs are limited
by the technologies available, and experimental manipulation would alter the recovery or loss of EVs.

by the release of their EVs suggesting that stem cell–
derived EVs can be used for stroke therapy as an alternative approach to stem cell infusion methods.31,32

CONCLUSIONS
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